About Minhyung Kim
Biography:
Dr. Kim practiced medicine as a surgeon in South Korea following the completion of an intensive general surgery residency program. He has been interested in medical research ever since he was a surgery resident and decided to move to the US in 2011. Since joining Roswell Park Comprehensive Cancer Center, he has developed a research program pertaining to the relationship between cell stress and organ transplantation that has depended on β2-adrenergic receptors in animal models. In addition, he is active investigating roles of regional cancer therapies using novel agents with various pharmaceutical companies. Also, he has launched training courses in microsurgical techniques and surgical skills for researchers from inside and outside Roswell Park. His laboratory has expertise in small animal models to recapitulate clinical scenarios in Comparative Oncology Shared Resource (COSR). He became a member of the CCSG CSB program in 2019 and was promoted to an Assistant Professor of Oncology in 2022.
Positions
- Assistant Professor of Oncology
- Comparative Oncology Shared Resource
Background
Education and Training:
- 2008 - MS - Medicine & Biology, College of Medicine The Catholic University of Korea, South Korea
- 2003 - MD - College of Medicine Seonam University, South Korea
Residency:
- 2008 - General Surgery, College of Medicine, The Catholic University of Korea, St. Mary’s hospital, Seoul, South Korea
Professional Memberships:
- American Association for Cancer Research Member
- Korean Medical Association Member
- Korean Surgical Society Member
Research
Research Overview:
- Development of preclinical models for regional cancer therapies
- Application of animal models for better understating in immune response after immunotherapy
- Augmentation of anti-PD-1 mAb immunotherapy by targeting liver-resident myeloid-derived suppressor cells (MDSC)
- Lymphocyte trafficking in cancer immunotherapy
- Investigation of immune modulation effects of β2-agonist on T cells and exploration of non-invasive biomarker for graft early rejection after vascularized composite tissue allograft transplantation (VCA)
Publications
- Kim M, Fisher DT, Powers CA, Repasky EA, Skitzki JJ. Improved cuff technique and intraoperative detection of vascular complications for hind limb transplantation in mice. Transplant Direct. 2018 Feb 2;4(2):e345. PMID: 29464206
- Visioni A, Kim M, Wilfong CD, Blum AB, Powers CA, Fisher DT, Gabriel E, Skitzki JJ. Intra-arterial versus Intra-venous adoptive cell therapy in a novel mouse model. J Immunother. 2018 Jul 5. PMID: 29985207
- Kim M, Fisher DT, Powers CA, Gabriel E, Korman A, Sexton S, Gudkov AV, Skitzki JJ. Novel mouse models of hepatic artery infusion (HAI). J Surg Res. 2017 Nov (219) 25-32. PMID: 29078890
- Kim M, Neznanov N, Wilfong CD, Fleyshman DI, Purmal AA, Haderski G, Baker P, Burkhart C, Gurova KV, Gudkov AV, Skitzki JJ. Preclinical validation of a single-treatment infusion modality that can eradicate extremity melanomas. Cancer Res. 2016 Nov 15;76(22):6620-6630. PMID: 27680682
- Kim M, Barone TA, Fedtsova N, Gleiberman A, Wilfong CD, Alosi JA, Plunkett RJ, Gudkov A, Skitzki JJ. A murine model of targeted infusion for intracranial tumors. J Neurooncol. 2016 Jan;126(1):37-45. PMID: 26376657